[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-adenomatous-polyp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-adenomatous-polyp":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,70,98,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":44,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100542405","early-detection-of-advanced-adenomas-and-colorectal-cancer-100542405",false,"NCT06342440","Early Detection of Advanced Adenomas and Colorectal Cancer","A Liquid Biopsy Assay For The Non-Invasive Early Detection of Advanced Adenomas and Colorectal Cancer","AACRC","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment.\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer syndromes (identified through genetic testing).\n* Inflammatory bowel diseases.\n* Lack of written informed consent.",true,"ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Colorectal Cancer","Colorectal Neoplasms","Colorectal Polyp","Colorectal Adenocarcinoma","Colorectal Disorders","Colorectal Dysplasia","Colorectal Cancer Stage I","Colorectal Cancer Stage II","Colorectal Cancer Stage III","Colorectal Cancer Stage IV","Colorectal Neoplasms Malignant","Colorectal Serrated Adenocarcinoma","Colorectal Adenoma With Severe Dysplasia","Colorectal Adenoma With Mild Dysplasia","Colorectal Adenoma With Moderate Dysplasia","Colorectal Adenoma and Carcinoma 1","Colorectal Adenomatous Polyp","Colorectal Adenocarcinoma Metastatic in the Liver",[45,46,47,48,49,50,51,52,53,54,55,56],"Early detection","Micro RNA","miRNA","Liquid biopsy","Machine learning","Artificial Intelligence","Incidence","Polypectomy","Screening","Surveillance","Exosome","Vascicles","RECRUITING","2026-06-15",{"date":60,"type":61},"2026-06-17","ACTUAL",{"date":63,"type":61},"2020-03-15",{"date":65,"type":22},"2026-06-18",{"name":67,"class":68},"City of Hope Medical Center","OTHER",6,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100487723","phase-1-testing-for-safety-and-colorectal-cancer-preventive-effects-of-onc201-100487723","NCT05630794","Testing for Safety and Colorectal Cancer Preventive Effects of ONC201","Phase I Trial of ONC201 for Chemoprevention of Colorectal Cancer","Inclusion Criteria:\n\n* Be identified as high risk for recurrent colorectal adenomas, as defined by:\n\n  * A diagnosis of FAP AND\u002FOR\n  * Findings of either \\> 5 small (less than 1 cm) adenomas OR \\>= 3 with at least one \\>= 10 mm on most recent colonoscopy performed in the past 5 years\n* Be \\>= 18 years of age on day of signing informed consent\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 1 (Karnofsky \\>= 70%)\n* Leukocytes \\>= 3,000\u002Fmicroliter\n* Absolute neutrophil count \\>= 1,000\u002Fmicroliter\n* Platelets \\>= 100,000\u002Fmicroliter\n* Total bilirubin within normal institutional limits\n* Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase (\\[SGPT\\]) =\\\u003C 1.5 x institutional upper limit of normal\n* Creatinine =\\\u003C 1.5 x institutional upper limit of normal\n* Participant is due to undergo a standard of care lower gastrointestinal (GI) colonoscopy for detection and removal of colorectal polyps. On this colonoscopy, participant is required to have:\n\n  * Two (2) adenomatous polyps of at least five (5) mm in size\n  * At least one (1) polyp within reach of a flexible sigmoidoscope (which will be retained in the colon or rectum and marked)\n  * In addition to polypectomy, six (6) biopsies of normal colonic mucosa \\>= 1 cm from a collected polyp will also be collected\n* Willing to undergo a second, research intent endoscopic procedure (either sigmoidoscopy or colonoscopy), approximately 12 weeks after initiating ONC201 treatment\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Life expectancy of at least 5-years\n* ONC201 is an imipridone agent with the potential for teratogenic or abortifacient effects. For this reason and because imipridones potential teratogenic effects are unknown, men and women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for four weeks after study treatment is completed. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should STOP the study medication and inform her study physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Prior history of hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome\n* Participants may not be currently receiving any other investigational agents or have received any investigational agents within the past four weeks\n* Prior history of invasive colorectal cancer\n* Prior invasive active neoplasm that is progressing or requires active treatment within 3 years from registration. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Participants with a history of prior invasive neoplasm diagnosed and treated greater than 3 years form registration may be considered with consultation of the primary investigator\n* Prior history of exposure to cytotoxic chemotherapy or ONC201\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant and women who are nursing are excluded from this study because ONC201 is an imipridone agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with ONC201, breastfeeding should be discontinued if the mother is treated with ONC201\n* Concomitant use of strong\u002Fmoderate CYP3A4\u002F5 inducers\u002Finhibitors. These agents must be discontinued at least 72-hours prior to beginning ONC201\n* Any of the following cardiac criteria:\n\n  * Prolongation of corrected QT (QTc) interval (QTc interval \\> 480 milliseconds, preferably using Frederica's QT correction formula), confirmed on electrocardiogram (ECG) tracings performed during screening\n  * A history of Torsades de pointes, heart failure, or family history of prolonged QT Syndrome\n* Concomitant use of drugs that are known to prolong QT and have a known risk of torsade de pointes (TdP) unless they are willing to stop these medications and possibly change to an alternative non-excluded medication to treat the same condition at least 72 hours prior to beginning ONC201",{"count":78,"type":22},36,"INTERVENTIONAL",[81],"PHASE1","The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps. People with familial adenomatous polyposis (FAP) or a history of multiple polyps are at higher than average risk of developing colorectal cancer. ONC201, now known as dordaviprone, is a drug that may stop cancer cells from growing. This drug has been shown in previous studies to cause cancer cell death but not harm normal cells. If successful, this study may help us develop a new option for colorectal cancer prevention.",[42,84,85,86],"Colorectal Carcinoma","Familial Adenomatous Polyposis","Multiple Adenomatous Polyps","2026-06-11",{"date":89,"type":61},"2026-06-12",{"date":91,"type":61},"2025-10-06",{"date":93,"type":22},"2028-03-01",{"name":95,"class":96},"National Cancer Institute (NCI)","NIH",5,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":79,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":127},"100515218","performance-and-safety-of-miwendo-assisted-colonoscopy-miwendo-ii-100515218","NCT05988645","Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)","Performance and Safety of MiWEndo-assisted Colonoscopy: MiWEndo II (Pivotal Study)","Inclusion Criteria:\n\n\\- Patients with a previously detected polyp in the rectum referred for resection.\n\nThese criteria will ensure the probability of finding polyps during the explorations.\n\nAll the patients will give written informed consent.\n\nExclusion Criteria:\n\n* Patients at a high risk of having major complications as perforation or hemorrhage, suspected or proven lower gastrointestinal bleeding, non-correctable coagulopathy or anticoagulant\u002Fclopidogrel therapy during procedure, inadequate bowel cleansing.\n* ASA-IV patients.\n* Urgent colonoscopy.",{"count":106,"type":22},50,[108],"NA","The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies (including phantom studies, an ex vivo study with human tissues, and an in vivo study with porcine model) and in a pilot study in humans (NCT05477836)",[26,28,111,42,29,27],"Colorectal Adenoma",[113,114,115,116],"microwave imaging","colonoscopy","early diagnosis","colorectal cancer screening","2025-09-23",{"date":119,"type":61},"2025-09-29",{"date":121,"type":61},"2023-08-01",{"date":123,"type":22},"2025-12-29",{"name":125,"class":126},"MiWEndo Solutions S.L.","INDUSTRY",1,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":18,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":79,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":127},"100568966","evaluation-of-gixams-efficacy-predicting-pre-cancerous-colorectal-polyps-and-colorectal-cancer-100568966","NCT06688110","Evaluation of Gixam's Efficacy Predicting Pre-cancerous Colorectal Polyps and Colorectal Cancer","Inclusion Criteria:\n\n1. Subjects aged ≥50 - ≤80 years.\n2. Able to provide a signed informed consent.\n3. Underwent FIT screening within the past 6 months with a positive result.\n4. Scheduled for a FIT positive screening colonoscopy at investigational site.\n\nExclusion Criteria:\n\n1. Has undergone colonoscopy within the past nine (9) years, except for a failed colonoscopy due to poor bowel preparation, which must have been performed within the past year without therapeutic intervention.\n2. Personal history of CRC.\n3. Family history of CRC, defined as having one or more first-degree relatives (parent, sibling, or child) with CRC at any age.\n4. Subject has a diagnosis or medical \u002F family history of any of the following conditions, including:\n\n   * Familial adenomatous polyposis (also referred to as \"FAP\", including attenuated FAP and Gardner's syndrome),\n   * Hereditary non-polyposis CRC syndrome (also referred to as \"HNPCC\" or \"Lynch Syndrome\"),\n   * Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis.\n5. Subject has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis, and\u002For Crohn's disease, and\u002For IBD-undefined.\n6. Subjects with the disability to extend their tongue.\n7. Subjects with tongue piercing.\n8. Dental visit in the 7 days prior to the Gixam test.\n9. Intake of pro-biotics over the past 3 months pre-Gixam test.\n10. Subject has any condition that in the opinion of the Investigator should preclude participation in the study.","50 Years","80 Years",{"count":137,"type":22},800,[108],"This is a prospective, single arm, multi-center clinical investigation aim to demonstrate the efficacy of Gixam in predicting the presence of premalignant colorectal polyps and colorectal cancer (CRC) in a fecal immunochemical test (FIT) positive population.",[26,42,27],"NOT_YET_RECRUITING","2024-11-13",{"date":144,"type":61},"2024-11-14",{"date":146,"type":22},"2025-02",{"date":148,"type":22},"2026-04",{"name":150,"class":126},"Jubaan Ltd."]